Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors
- PMID: 22797391
- DOI: 10.6092/1590-8577/965
Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors
Abstract
Neuroendocrine tumors (NETs) describe a heterogeneous group of tumors with a wide range of morphologic, functional, and behavioral characteristics. These tumors are often indolent but they have the potential to cause symptoms through release of hormones and through local or distant spread. Pancreatic neuroendocrine tumors (pNET) represent a subset of NETs and they have a unique pattern of symptoms and disease progression. Due to the heterogeneity of this disease it is important to identify reliable markers to help guide prognosis and predict response to therapy. The recent approval of two new agents in the treatment of advanced pNET has raised additional interest in the significance of molecular markers in this disease. At the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, several investigators reported on collaborative efforts to develop clinically useful biomarkers for this disease. Choti et al. (Abstract #4126) reported data about the functional characteristics of NETs and pNETs among a multi-institutional cohort finding that a substantial minority of patients have functional symptoms even when the disease is localized. Faggiano et al. (Abstract #1604) looked at a wide spectrum of NETs in several referral centers and reported on predictors of both short term and long term survival in this setting. Yao et al. (Abstract #4014) reported analysis of predictive biomarkers among patients in the RADIANT-2 trial which looked at the role of the mTOR inhibitor, everolimus compared to placebo in NET. Fischer et al. (Abstract #4128) looked at a novel biomarker, placental growth factor (PlGF) and evaluated the role of serum and tissue levels of this protein as a predictive marker. Finally, Khan et al. (Abstract #4123) investigated the role of circulating tumor cells in NET (and pNET) and found that this may have potential as a prognostic marker and an early marker of response to therapy. The authors review and summarize these abstracts in this article.
Similar articles
-
Pancreatic neuroendocrine tumors: entering a new era.JOP. 2012 Mar 10;13(2):169-73. JOP. 2012. PMID: 22406593 Review.
-
Update on novel therapies for pancreatic neuroendocrine tumors.JOP. 2012 Jul 10;13(4):372-5. doi: 10.6092/1590-8577/964. JOP. 2012. PMID: 22797392
-
Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.Endocr Relat Cancer. 2013 May 20;20(3):305-19. doi: 10.1530/ERC-12-0223. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23463017
-
Biomarkers in neuroendocrine tumors.JOP. 2013 Jul 10;14(4):372-6. doi: 10.6092/1590-8577/1692. JOP. 2013. PMID: 23846930
-
Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.JOP. 2011 Jul 8;12(4):358-61. JOP. 2011. PMID: 21737896 Review.
Cited by
-
Challenges in circulating tumor cell detection by the CellSearch system.Mol Oncol. 2016 Mar;10(3):395-407. doi: 10.1016/j.molonc.2015.12.002. Epub 2015 Dec 25. Mol Oncol. 2016. PMID: 26795350 Free PMC article. Review.
-
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.World J Gastrointest Oncol. 2016 Apr 15;8(4):389-401. doi: 10.4251/wjgo.v8.i4.389. World J Gastrointest Oncol. 2016. PMID: 27096034 Free PMC article. Review.
-
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.Theranostics. 2014 Jan 29;4(4):336-65. doi: 10.7150/thno.7851. eCollection 2014. Theranostics. 2014. PMID: 24578720 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous